Neose Technologies, Inc. has been notified by the regulatory authority in a Western European jurisdiction that it can commence human clinical trials for NE-180, the company's long-acting, GlycoPEGylated erythropoietin for the treatment of anaemia.

The company expects to initiate a Phase I, single ascending-dose trial in healthy volunteers next month and conclude the trial in mid-2006.

Neose is a biopharmaceutical company using its proprietary enzymatic technologies to develop improved drugs, focusing primarily on therapeutic proteins. Neose uses its GlycoAdvance and GlycoPEGylation technologies to develop improved versions of drugs with proven safety and efficacy.